Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide

NCT04669665 is registered in ClinicalTrials.gov with Seelos Therapeutics, Inc. as lead sponsor.

NCT NCT04669665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide
Lead sponsor
Seelos Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 17, 2020
Completion date
July 14, 2023
Enrollment
164 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major, suicidal